FDA halts sale of genetic test sold to consumersBMJ 2013; 347 doi: https://doi.org/10.1136/bmj.f7126 (Published 27 November 2013) Cite this as: BMJ 2013;347:f7126
- Mike McCarthy
The US Food and Drug Administration has ordered 23andMe, which sells genetic testing directly to consumers, to stop marketing its popular $99 (£60; €73) home testing service.
For the test consumers provide a DNA sample by spitting into the company’s “DNA spit kit” and mail it for analysis.
The company claims that its Personal Genome Service (PGS) is capable of identifying more than 250 genetic risk markers for disease and adverse drug reactions. The company claims …
Log in using your username and password
Log in through your institution
Sign up for a free trial